The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes

The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes

<strong>Aims:</strong> Small, short studies suggest metformin influences the glucagon-like peptide (GLP)-1 axis in individuals with and without type 2 diabetes (T2DM). In the Carotid Atherosclerosis: Metformin for insulin ResistAnce (CAMERA) trial (NCT00723307) we investigated whether th...

Detaylı Bibliyografya
Asıl Yazarlar:	Preiss, D, Dawed, A, Welsh, P, Heggie, A, Jones, A, Dekker, J, Koivula, R, Hansen, T, DIRECT consortium, Stewart, C, Holman, R, Franks, P, Walker, M, Pearson, E, Sattar, N
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	Wiley 2016

Benzer Materyaller

Metformin therapy and circulating NT-proBNP levels: the CAMERA trial
Yazar:: Preiss, D, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study: Metabolism
Yazar:: Preiss, D, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Associations of targeted circulating microRNAs with insulin resistance in the CAMERA (Carotid Atherosclerosis: MEtformin for insulin ResistAnce) trial
Yazar:: Alramah, T, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial
Yazar:: Preiss, D, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Yazar:: Preiss, D, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Putative miRNA biomarkers of insulin resistance and the effect of metformin: data from the CAMERA trial
Yazar:: ALRamah, T, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Risk of anaemia with long-term metformin use in a community setting
Yazar:: Donnelly, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
Yazar:: Anna Skowronek, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
Yazar:: Mafham, M, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Metformin and risk of cardiovascular disease.
Yazar:: Turner, R, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Abcc5 knockout mice have lower fat mass and increased levels of circulating GLP‐1
Yazar:: Cyranka, M, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Circulating GLP-1 Levels in Patients with Pheochromocytoma/Paraganglioma
Yazar:: Nan Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

GLP-1 Increases Circulating Leptin Levels in Truncal Vagotomized Rats
Yazar:: Tiago Morais, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
Yazar:: Iryna Halabitska, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome
Yazar:: Dorte Glintborg, ve diğerleri
Baskı/Yayın Bilgisi: (2017-06-01)

METFORMIN IN THE MANAGEMENT OF TYPE-2 DIABETES - REPLY
Yazar:: Holman, R, ve diğerleri
Baskı/Yayın Bilgisi: (1989)

Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists
Yazar:: Mayeesha Ahmed, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Metformin as first choice in oral diabetes treatment: the UKPDS experience.
Yazar:: Holman, R
Baskı/Yayın Bilgisi: (2007)

Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.
Yazar:: Rankin, N, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

GDF15 mediates the effects of metformin on body weight and energy balance
Yazar:: Coll, A, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Metformin and mortality. Reply to Lund SS [letter]
Yazar:: Stevens, R, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Metformin and mortality. Reply to Lund SS [letter].
Yazar:: Stevens, R, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
Yazar:: Chloé Amouyal, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

The effect of metformin treatment on the level of GLP-1, NT-proBNP and endothelin-1 in patients with type 2 diabetes mellitus
Yazar:: L.K. Sokolova, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Cost utility analysis of intensive blood-glucose control, tight blood pressure control and metformin in patients with Type 2 diabetes
Yazar:: Clarke, P, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Yazar:: Kristensen, SL, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
Yazar:: Andrea Etrusco, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Metformin Pharmacogenetics and SLC2A2: Genome-Wide Association Study and 2-stage replication in GoDARTS and UKPDS
Yazar:: Zhou, K, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
Yazar:: Shan Lang, ve diğerleri
Baskı/Yayın Bilgisi: (2020-04-01)

Proglucagon Promoter Cre-Mediated AMPK Deletion in Mice Increases Circulating GLP-1 Levels and Oral Glucose Tolerance.
Yazar:: Sophie R Sayers, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review
Yazar:: Katherine G. Young, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2
Yazar:: Elisabeth Carydias, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
Yazar:: Mette Simone Aae Madsen, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
Yazar:: Griffin, SJ, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Effects of GLP-1(9-36) and exendin-4 on glucagon secretion from human islets of Langerhans: evidence of a novel GLP-1 receptor in islets?
Yazar:: Ramracheya, R, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
Yazar:: Wright, A, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Metformin-regulated glucose flux from the circulation to the intestinal lumen
Yazar:: Kazuhiko Sakaguchi, ve diğerleri
Baskı/Yayın Bilgisi: (2025-03-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
Yazar:: C. Meurot, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Fasting GLP-1 Levels in Women with PCOS and CAH
Yazar:: Robeva R., ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study.
Yazar:: Gudmundsdottir, V, ve diğerleri
Baskı/Yayın Bilgisi: (2018)